Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer-Reference-Cited by-同舟云学术

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer

Published:2017-06-27 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Chan David Lok Hang¹,Segelov Eva²,Wong Rachel SH³,Smith Annabel⁴,Herbertson Rebecca A⁵,Li Bob T.⁶,Tebbutt Niall⁷,Price Timothy⁸,Pavlakis Nick¹

Affiliation:

1. Royal North Shore Hospital; Department of Medical Oncology; St Leonards New South Wales Australia 2065

2. Monash University and Monash Health; Department of Oncology; Lvl 7, MHTP building, Monash Health 240 Clayton Rd Clayton Victoria Australia 3168

3. University of Sydney; Department of Medicine; Sydney NSW Australia 2006

4. University of New South Wales; Department of Medicine; Sydney NSW Australia 2052

5. Ludwig Institute for Cancer Research; Melbourne Centre for Clinical Sciences; Austin Hospital HSB1 145-163 Studley Road Heidelberg Victoria Australia 3084

6. Memorial Sloan Kettering Cancer Center; Thoracic Oncology and Early Drug Development Service; 1275 York Avenue New York NY USA 10065

7. Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital; Olivia Newton-John Cancer Research Institute; 145-163 Studley Rd Heidelberg Victoria Australia 3084

8. Olivia Newton-John Cancer Wellness & Research Centre, Austin Hospital; Olivia Newton-John Cancer Research Institute, Level 5; 145-163 Studley Rd Heidelberg Victoria Australia 3084

Publisher

Wiley

Subject

Pharmacology (medical)

Reference210 articles.

1. Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC);Adams;Journal of Clinical Oncology,2012

2. Epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab therapy in combination with oxaliplatin (Ox) and 5FU in first-line treatment of advanced colorectal cancer (aCRC);Adams;Journal of Clinical Oncology,2012

3. Epidermal growth factor receptor (EGFR) as a predictive and prognostic marker in patients with advanced colorectal cancer (aCRC): The MRC COIN trial experience;Adams;Journal of Clinical Oncology Conference: 2011 Gastrointestinal Cancers Symposium,2011

4. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience;Adams;British Journal of Cancer,2009

5. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial;Adams;Lancet,2011

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress on Colorectal Cancer Me-tastasis Mechanisms and Targeted Therapy;Advances in Clinical Medicine;2024

2. Targeting beta-catenin signaling for prevention of colorectal cancer – Nutraceutical, drug, and dietary options;European Journal of Pharmacology;2023-10

3. Clusterin Expression in Colorectal Carcinomas;International Journal of Molecular Sciences;2023-09-27

4. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer;Current Issues in Molecular Biology;2023-09-26

5. Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer;Value in Health Regional Issues;2023-09